CY1124480T1 - Βελτιωμενη διεργασια για τη συνθεση του συνδετη-φαρμακου vc-seco - Google Patents

Βελτιωμενη διεργασια για τη συνθεση του συνδετη-φαρμακου vc-seco

Info

Publication number
CY1124480T1
CY1124480T1 CY20211100786T CY211100786T CY1124480T1 CY 1124480 T1 CY1124480 T1 CY 1124480T1 CY 20211100786 T CY20211100786 T CY 20211100786T CY 211100786 T CY211100786 T CY 211100786T CY 1124480 T1 CY1124480 T1 CY 1124480T1
Authority
CY
Cyprus
Prior art keywords
seco
synthesis
improved process
drug
drug binder
Prior art date
Application number
CY20211100786T
Other languages
English (en)
Inventor
Vladimír JANOUSEK
Martin Kás
Original Assignee
Byondis B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byondis B.V. filed Critical Byondis B.V.
Publication of CY1124480T1 publication Critical patent/CY1124480T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η παρούσα εφεύρεση αφορά μία βελτιωμένη διεργασία για τη σύνθεση συνδέτη-φαρμάκου vc-seco-DUBA και ενδιαμέσων ενώσεων αυτού, όπως επίσης τη χρήση της εν λόγω βελτιωμένης διεργασίας σε μία διεργασία για την παρασκευή ενός συζεύγματος αντισώματος-φαρμάκου που περιλαμβάνει τον συνδέτη-φάρμακο vc-seco-DUBA.
CY20211100786T 2017-11-24 2021-09-06 Βελτιωμενη διεργασια για τη συνθεση του συνδετη-φαρμακου vc-seco CY1124480T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17203457 2017-11-24
PCT/EP2018/082199 WO2019101850A1 (en) 2017-11-24 2018-11-22 Improved process for the synthesis of linker-drug vc-seco-duba

Publications (1)

Publication Number Publication Date
CY1124480T1 true CY1124480T1 (el) 2022-07-22

Family

ID=60452506

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100786T CY1124480T1 (el) 2017-11-24 2021-09-06 Βελτιωμενη διεργασια για τη συνθεση του συνδετη-φαρμακου vc-seco

Country Status (16)

Country Link
US (1) US11633492B2 (el)
EP (1) EP3713939B1 (el)
JP (1) JP7279042B2 (el)
KR (1) KR20200091431A (el)
CN (1) CN111556870B (el)
AU (1) AU2018371966B2 (el)
CA (1) CA3083169A1 (el)
CY (1) CY1124480T1 (el)
DK (1) DK3713939T3 (el)
ES (1) ES2889775T3 (el)
HR (1) HRP20211435T1 (el)
HU (1) HUE055305T2 (el)
LT (1) LT3713939T (el)
PL (1) PL3713939T3 (el)
PT (1) PT3713939T (el)
WO (1) WO2019101850A1 (el)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
AU2010293028B2 (en) 2009-09-08 2014-12-18 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof
KR101901555B1 (ko) * 2010-04-21 2018-09-21 신타가 비.브이. Ｃｃ―１０６５ 유사체와 2작용성 링커의 신규한 콘쥬게이트
DK3151865T3 (da) * 2014-05-22 2021-10-25 Byondis Bv Stedsspecifik konjugation af linker medicin til antistof og resulterende adcs
EP3152191B1 (en) 2014-06-05 2019-05-15 Synthon Biopharmaceuticals B.V. Improved process for making duocarmycin prodrugs
JP2015199772A (ja) 2015-06-25 2015-11-12 シグネーチャー セラピューティクス，インク．Ｓｉｇｎａｔｕｒｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 酵素切断可能なオピオイドプロドラッグとそのインヒビターとを含んでなる組成物
HUE050726T2 (hu) 2016-02-12 2021-01-28 Byondis Bv Génsebészeti eljárással bejuttatott ciszteint tartalmazó ellenanyagok szelektív redukálása
JP7058666B2 (ja) 2016-11-25 2022-04-22 マブウェル （シャンハイ） バイオサイエンス カンパニー リミテッド 抗体－薬物複合体化のための二置換マレインアミドリンカーならびにその調製方法および使用

Also Published As

Publication number Publication date
WO2019101850A1 (en) 2019-05-31
AU2018371966A1 (en) 2020-06-18
DK3713939T3 (da) 2021-09-13
US20200368362A1 (en) 2020-11-26
RU2020120838A3 (el) 2022-03-03
PT3713939T (pt) 2021-09-16
CA3083169A1 (en) 2019-05-31
JP7279042B2 (ja) 2023-05-22
CN111556870B (zh) 2023-09-29
HUE055305T2 (hu) 2021-11-29
AU2018371966B2 (en) 2021-02-25
HRP20211435T1 (hr) 2022-01-07
EP3713939B1 (en) 2021-07-21
RU2020120838A (ru) 2021-12-24
CN111556870A (zh) 2020-08-18
US11633492B2 (en) 2023-04-25
ES2889775T3 (es) 2022-01-13
JP2021504351A (ja) 2021-02-15
KR20200091431A (ko) 2020-07-30
LT3713939T (lt) 2021-10-25
EP3713939A1 (en) 2020-09-30
PL3713939T3 (pl) 2021-12-13

Similar Documents

Publication Publication Date Title
CY1122472T1 (el) Συζευγμα-αντισωματος-φαρμακου και η χρηση αυτου για την αγωγη του καρκινου
CY1124756T1 (el) Εξουδετερωτικα αντισωματα του ιου ανθρωπινης ανοσοανεπαρκειας
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
CO2018004152A2 (es) Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso
BR112016024525A2 (pt) novos anticorpos anti-rnf43 e métodos de uso
EA201691650A1 (ru) Гидрофильные конъюгаты антитело-лекарственное средство
CY1121849T1 (el) Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου
MX2021008334A (es) Ligadores que modulan la estabilidad para usar con conjugados anticuerpo-farmaco.
CO2018005433A2 (es) Conjugados de fármaco de anticuerpo her2 específicos de sitio
PE20150892A1 (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco
EA201890530A1 (ru) Конъюгаты антитела к dll3 и лекарственного средства и способы их применения
CY1120452T1 (el) Παραγωγο αμιδιου πυραζολης
BR112019023246A8 (pt) melhorias farmacocinéticas de quelatos bifuncionais e usos dos mesmos
CY1121783T1 (el) Συζευγμα αντισωματος-igf-1r-φαρμακου και η χρηση αυτου για την αγωγη του καρκινου
EA201892040A1 (ru) Способ получения пегилированных соединений лекарственный препарат - линкер и их промежуточных соединений
BR112018075651A2 (pt) anticorpos anti-cd98 e conjugados anticorpo fármaco
EA201792590A1 (ru) КОНЪЮГАТ АНТИТЕЛА ПРОТИВ ErbB2 И ЛЕКАРСТВЕННОГО СРЕДСТВА И ЕГО КОМПОЗИЦИЯ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ
CY1123231T1 (el) Ενωσεις τετραϋδροπυριμιδοδιαζεπινης και τετραϋδροπυριδοδιαζεπινης για θεραπεια πονου και καταστασεων σχετικων με τον πονο
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
BR112018075644A2 (pt) anticorpos anti-cd98 e conjugados de anticorpo e fármaco
BR112018075630A2 (pt) anticorpos anti-cd98 e conjugados de fármaco de anticorpo
CY1124529T1 (el) Ενωσεις λευκοχρυσου λειτουργικοποιημενες με μονομηλεινιμιδιο για θεραπεια καρκινου
CY1121187T1 (el) Ενα εκχυλισμα απο indigo naturalis και μια διεργασια για την παρασκευη εκεινου
EA201991196A1 (ru) Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментов
CY1124748T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν δοραβιρινη, φουμαρικη δισοπροξιλη τενοφοβιρης και λαμιβουδινη